Inhibition of Prostate Cancer Growth by a Growth Hormone-Releasing Hormone Antagonist
Author Information
Author(s): A Jungwirth, AV Schally, J Pinski, G Halmos, K Groot, P Armatis, M Vadillo-Buenfil
Primary Institution: Tulane University School of Medicine
Hypothesis
Can the GH-RH antagonist MZ-4-71 inhibit the growth of androgen-independent prostate cancers?
Conclusion
The GH-RH antagonist MZ-4-71 significantly inhibits the growth of androgen-independent prostate cancers in animal models.
Supporting Evidence
- MZ-4-71 reduced tumor volume in DU-145 and PC-3 prostate cancers significantly.
- Serum levels of GH and IGF-I were significantly decreased in treated animals.
- Treatment with MZ-4-71 prolonged tumor doubling time in both DU-145 and PC-3 tumors.
Takeaway
A new medicine called MZ-4-71 can help stop the growth of certain prostate cancers in mice.
Methodology
The study involved treating nude mice and rats with the GH-RH antagonist MZ-4-71 and measuring tumor growth and hormone levels.
Limitations
The study was conducted in animal models, which may not fully represent human responses.
Participant Demographics
Male athymic nude mice and Copenhagen rats were used in the study.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website